Clinical Trials Logo

Fabry Disease clinical trials

View clinical trials related to Fabry Disease.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT01031173 No longer available - Fabry Disease Clinical Trials

Treatment Protocol of Replagal for Patients With Fabry Disease

Start date: n/a
Phase:
Study type: Expanded Access

The study will evaluate the safety and efficacy of Replagal® (agalsidase alfa) at a dose of 0.2 mg/kg infused intravenously (IV) over 40 minutes, every other week. The study will monitor the course of disease in males and females with Fabry disease who are naive to treatment or were previously treated with agalsidase beta (Fabrazyme®).